A combination of PD-1 and TIGIT immune checkpoint inhibitors elicits a strong anti-tumour response in mesothelioma

A combination of PD-1 and TIGIT immune checkpoint inhibitors elicits a strong anti-tumour response in mesothelioma

Abstract Background Finding effective and curative treatment for mesothelioma remains challenging. While the introduction of immunotherapy combinations using ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) have offered hope for some patients, a large proportion of mesothelioma cases, particularly...

Full description

Saved in:
Bibliographic Details
Main Authors: Huaikai Shi, Ta-Kun Yu, Ben Johnson, Sakthi Priya Selvamani, Ling Zhuang, Kenneth Lee, Sonja Klebe, Samuel Smith, Kirby Wong, Kate Chen, Georgina Clark, Emma M. Rath, Holly Pearson, David Gallego Ortega, Anthony Linton, Steven Kao, Pablo Silveira, Yuen Yee Cheng
Format: Article
Language:English
Published: BMC 2025-02-01
Series:Journal of Experimental & Clinical Cancer Research
Online Access:https://doi.org/10.1186/s13046-025-03314-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13046-025-03314-w

Similar Items